Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph early_phase_1
2
50%
Ph phase_3
2
50%

Phase Distribution

2

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Other(1)

Detailed Status

Recruiting2
Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 12 (50.0%)
Phase 32 (50.0%)

Trials by Status

completed125%
recruiting250%
unknown125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingearly_phase_1

Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503

NCT06303921
recruitingearly_phase_1

Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

NCT06932809
unknownphase_3

Multimodal Biomarkers for Diagnosis and Prognosis in VCI

NCT04604600
completedphase_3

Application of Amyloid PET in Cerebral Amyloid Angiopathy

NCT03542656

Clinical Trials (4)

Showing 4 of 4 trials
NCT06303921Early Phase 1

Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503

Recruiting
NCT06932809Early Phase 1

Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

Recruiting
NCT04604600Phase 3

Multimodal Biomarkers for Diagnosis and Prognosis in VCI

Unknown
NCT03542656Phase 3

Application of Amyloid PET in Cerebral Amyloid Angiopathy

Completed

All 4 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
4